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Abstract Introduction: Many consequences of cerebrovascular disease are identifiable by magnetic reso-
nance imaging (MRI), but variation in methods limits multicenter studies and pooling of data. The
European Union Joint Program on Neurodegenerative Diseases (EU JPND) funded the HARmo-
Nizing Brain Imaging MEthodS for VaScular Contributions to Neurodegeneration (HARNESS)
initiative, with a focus on cerebral small vessel disease.
Methods: Surveys, teleconferences, and an in-person workshop were used to identify gaps in knowl-
edge and to develop tools for harmonizing imaging and analysis.
Results: A framework for neuroimaging biomarker development was developed based on validating
repeatability and reproducibility, biological principles, and feasibility of implementation. The status
of current MRI biomarkers was reviewed. Awebsite was created at www.harness-neuroimaging.org
with acquisition protocols, a software database, rating scales and case report forms, and a deidentified
MRI repository.
Conclusions: The HARNESS initiative provides resources to reduce variability in measurement in
MRI studies of cerebral small vessel disease.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
Vascular disease contributes to more than half of dementia
cases, often in conjunction with Alzheimer’s disease pathol-
ogy [1]. Most of the vascular brain injury is caused by cere-
bral small vessel disease (cSVD) [2], which often goes
clinically unrecognized until revealed by brain imaging.
cSVD is strongly associated with cognitive impairment and
future risk for cognitive decline and dementia [3,4]. One of
the challenging but intriguing aspects of research in this
field is that cSVD has diverse manifestations, including
brain infarcts, lacunes, white matter hyperintensity (WMH)
of presumed vascular origin, perivascular spaces, and
microbleeds [5]. In addition, several promising new imaging
biomarkers are emerging for the diagnosis and monitoring of
patients, as well as for studies into etiology and pathophysi-
ology [6,7].
Establishing the Standards for Reporting Vascular
Changes on Neuroimaging (STRIVE) [5] was an important
first step to harmonize neuroimaging assessment of cSVD.
Terms and definitions for common cSVD lesion types, re-
porting standards, and suggestions for acquisition protocols
were provided and are now commonly used in research
practice. However, STRIVE did not address pathways for
developing and validating new biomarkers, nor did it address
sources of variability in measurement, which should be
minimized to enhance the ability to detect biological differ-
ences in multicenter and longitudinal studies.
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To fully realize the potential of neuroimaging biomarkers
of cSVD for use in larger scale, multicenter studies including
clinical trials with cSVD endpoints, we created the HARmo-
Nizing Brain Imaging MEthodS for VaScular Contributions
to Neurodegeneration (HARNESS) initiative. This initiative
builds on the work of STRIVE by defining a framework for
developing neuroimaging biomarkers of cSVD, reviewing
the status of emerging neuroimaging biomarkers in this field,
and developing and implementing standardized acquisition
protocols and Web-based repositories to facilitate multi-
center research.
2. Methods
2.1. HARNESS group composition
HARNESS was funded by the international Joint Pro-
gram for Neurodegenerative Diseases initiative to analyze
the role of neuroimaging biomarkers in neurodegeneration
and dementia. The HARNESS members were invited to
participate based on their contributions to cSVD research,
including their participation in STRIVE, and to provide a
balance of input from different geographic regions and
research disciplines. HARNESS included 70 members
from 29 institutions in 11 countries, representing disciplines
including radiology, biomedical engineering, clinical trials,
computer science, epidemiology, medical biophysics,
neurology, stroke medicine, and psychiatry. Members were
surveyed to identify important needs for harmonizing neuro-
imaging methods for cSVD and then subdivided into 11
working groups of 6–12 participants representing a range
of disciplines, cSVD interests, and location to address these
needs. The initiative commenced in July 2016 and culmi-
nated in an in-person conference in June 2017.Where appro-
priate, working groups identified relevant articles through
literature searches, expert knowledge, and hand searching
articles from reference lists, but formal systematic reviews
and creation of evidence tables were considered out of
scope.
3. Results
3.1. Neuroimaging biomarker framework for cSVD
We adopted the definition of a biomarker used by the Bio-
markers Definitions Working Group [8]: “a characteristic
that is objectively measured and evaluated as an indicator
of normal biological processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention”.
Inherent to this definition is that biomarkers may have
different clinical purposes, including diagnosis, prognosis,
monitoring, and measuring treatment response. Biomarkers
have been used as surrogate endpoints for clinical trials,
meaning that the biomarker substitutes for or represents a
manifestation of the clinical endpoint, when the biomarker
is expected to predict “clinical benefit or harm based on
epidemiologic, therapeutic, pathophysiologic, or other sci-
entific evidence” [9]. This might be considered the highest
level of qualification for a biomarker. However, biomarkers
have other important uses for investigation, diagnosis, and
monitoring of disease even if they do not predict treatment
response.
Validation is required to determine whether a biomarker
can be considered fit for a specific purpose. Some regulatory
authorities, such as the US Food and Drug Administration,
define a formal process of biomarker qualification for use
in evaluating therapeutics [10]. To our knowledge, no
biomarker of cSVD, including WMH, lacunes, or micro-
bleeds, has yet been submitted to and qualified by the US
Food and Drug Administration for use in clinical trials,
although they have been used as secondary endpoints in im-
aging substudies [11]. Qualification of an imaging marker
that can be used as a trial endpoint would greatly accelerate
the development of therapies for cSVD by improving selec-
tion criteria, reducing the size and cost of a trial, and
increasing the specificity of the outcome.
To facilitate validation of cSVD biomarkers, we present a
framework for neuroimaging biomarker development in
Fig. 1, adapted from consensus recommendations from the
European Society of Radiology [12], and for development
of imaging biomarkers for oncology [13]. Validation has
technical aspects (e.g., can the same measurement be repro-
duced reliably on the same scanner or different scanners?),
biological aspects (e.g., is the measurement different in pa-
tients with vs. without cSVD?), and feasibility of implemen-
tation (e.g., is the measurement practical and affordable?). In
our version of this biomarker-development framework, we
define proof of concept as validation of measurement of a
specific change or process (e.g., arterial spin-labeling
[ASL] magnetic resonance imaging [MRI] generates a
signal that correlates with gold standard measurement of
perfusion), whereas proof of principle refers to validation
that the measurement distinguishes cases from controls or
is associated with health outcomes (e.g., ASL-measured
perfusion is different in cSVD patients compared with that
in controls and is associated with worse prognosis) [12].
We define proof of effectiveness as the ability to measure
the marker across larger groups of patients at multiple sites
[12]. Repeatability refers to the precision of repeated mea-
surements under the same conditions using the same scanner
(with high repeatability conferring greater power to detect
smaller within-individual changes over time, important for
longitudinal studies), and reproducibility refers to the preci-
sion of replicate measurements on the same or similar ob-
jects (e.g., a phantom or human volunteers) using different
scanners [12,13]. For visual assessments by human raters,
intrarater reliability refers to the precision of measurement
by the same rater, whereas interrater reliability refers to
the precision of measurements across different raters. The
Quantitative Imaging Biomarker Alliance offers
recommendations for study design and statistical
approaches to technical validation [14]. Validation typically
begins with relatively small, cross-sectional studies at single
E.E. Smith et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (2019) 191-204 193
centers to demonstrate proof of concept, proof of principle,
and initial technical validation before expanding to longitu-
dinal studies and multicenter studies to demonstrate proof of
effectiveness and reproducibility. Feasibility is then demon-
strated by incorporation of the biomarker into clinical radio-
logical practice or by qualification for use in clinical trials.
3.2. Survey of current cSVD biomarker development with
specific considerations for selected emerging modalities
Commonly studied neuroimaging biomarkers of cSVD
are lacunes, WMH of presumed vascular origin, and cerebral
microbleeds. These lesions are typically reported in routine
radiology practice and have been incorporated as secondary
imaging endpoints in some clinical trials. For these markers,
proof of concept, principle, and effectiveness have been es-
tablished. Even so, longitudinal data on change over time
and data on repeatability and reproducibility, so important
for planning sample sizes in clinical trials, are relatively
scant [15,16].
A recent systematic review highlighted the gaps in
knowledge in repeatability and reproducibility of measure-
ments of cSVD lesions, focusing mostly on quantitative bio-
markers including volumes of WMH, lacunes, and brain
[17]. The authors systematically searched the literature to
identify information on scan-rescan repeatability (which
they termed “within-center reproducibility”) and the effects
of scanner vendor, field strength, sequence choices, and coil
type. They found that the number of studies on repeatability
and reproducibility varied widely by lesion type. The largest
number of studies was found for measures of brain volume,
probably because brain atrophy is an important biomarker
for many neurological diseases in addition to cSVD, such
as Alzheimer’s disease, and because phantoms are available
for measuring variations in geometric distortions across
scanners. For WMH, lacunes, perivascular spaces, and mi-
crobleeds, therewas only sparse information on repeatability
with, relatively speaking, the greatest amount of information
on WMH measurements cross-sectionally, but no repeat-
ability data on longitudinal measurements.
Fig. 2 provides an overview of the validation status of the
best established cSVDmarkers and emerging modalities and
techniques. Over time, the list of neuroimaging biomarkers
of cSVD has grown substantially as our knowledge of
Fig. 1. Imaging biomarker development framework for cerebral small vessel disease.
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cSVD pathophysiology [2], and ability to image it, has
grown.
Some markers have already received a large amount of
attention, notably WMH (assessed visually or computation-
ally), lacunes, and microbleeds (mainly visually with some
emerging computational methods). Even so, some aspects
of validation are lacking with few large comparisons of
different volumetric tools and little longitudinal data, and
none are yet adopted as confirmed surrogate outcomes in
clinical trials. Nonetheless, they have already been the sub-
ject of many reviews [16,17].
Hence, the list of biomarkers discussed in detail here rep-
resents the subset that the HARNESS group selected as the
next most promising biomarkers for measuring unique as-
pects of cSVD pathophysiology, which have so far received
less attention. The list is not exhaustive. Future research will
likely add more modalities and lesion types. For example,
microinfarcts have been visualized on MRI by several
research groups and may be a frequent but underrecognized
consequence of thrombosis or embolism of small arteries
[18]. In addition, future research may clarify that biomarkers
currently on the list are a poor fit for some purposes.
In the following sections, we review the state of imaging
biomarker development for selected emerging modalities,
along with considerations for further development and
harmonization.
3.3. Structural imaging: perivascular spaces
Perivascular spaces are rapidly emerging as a novel
marker of cSVD and are defined as “fluid-filled spaces that
follow the typical course of a vessel as it goes through
gray or white matter” [5]. Although long considered an
innocuous phenomenon of aging, a converging body of proof
of principle cross-sectional studies now suggests that a
larger burden of perivascular spaces is associated with a
higher likelihood of dementia, cognitive impairment, and
stroke [19–21]. More importantly, these associations are
independent from established markers of cSVD.
Longitudinal studies of the appearance of perivascular
spaces or their enlargement over time are lacking;
therefore, the rate at which these spaces change over time
is essentially unknown. One study showed that the 5-year
incidence of new large perivascular spaces (defined as
3 mm diameter) in a general elderly population was
3.1% [21]; however, this size exceeds the generally accepted
current width boundary between perivascular spaces and
lacunes [5].
There are few data on the repeatability of measurements
of perivascular spaces and reproducibility of measurement
across scanners. For one automated method, repeatability
was excellent with intraclass correlations of 0.92 for basal
ganglia and 0.87 for centrum semiovale [22]. In contrast,
Fig. 2. Schematic overview of the neuroimaging biomarker development status for cerebral small vessel disease. The green light indicates validation data from
two or more studies from independent research groups; yellow light indicates support from a single study or conflicting evidence from multiple studies; and red
light indicates there is currently insufficient evidence. Abbreviations: WMH, white matter hyperintensities of presumed vascular origin; CMB, cerebral micro-
bleeds; PVS, perivascular spaces; DTI, diffusion tensor imaging; BBB, blood-brain barrier. Proof of concept: evidence that the marker measures a specific
change or process related to cerebral small vessel disease. Proof of principle/mechanism: evidence that the marker differs between patients with and without
cerebral small vessel disease. Proof of effectiveness: evidence from larger scale multiple center studies that the marker differs between patients with and without
cerebral small vessel disease. Repeatability: precision of repeated measurements under the same conditions using the same scanner. Reproducibility: replicate
measurements on the same or similar objects (e.g., a phantom or human volunteers) in different locations using different scanners. Longitudinal: the rate of
change over time has been defined. Monitoring: evidence that longitudinal changes in the marker are associated with progression of cerebral small vessel dis-
ease. Surrogate: evidence that changes in the marker are strongly associated with clinical outcomes in cerebral small vessel disease, such that changes in the
marker could be considered a substitute for a clinical endpoint.
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intrarater reliability and interrater reliability for visual rating
scales have been published by several groups and should be
expected to be good to excellent (i.e., with kappa values of
0.5 or higher or intraclass correlation coefficients of 0.6 or
higher). Rating on T2-weighted sequences is favored
because perivascular spaces are well visible, but some
studies have used high-resolution T1-weighted sequences
instead. In one study, ratings on T1-weighted and T2-
weighted sequences showed excellent correlation (intraclass
correlation . 0.80) [23].
The HARNESS working group identified several diffi-
culties in the quantification of perivascular spaces, which
have so far hampered comprehensive understanding of their
biological meaning. First, perivascular spaces, reflecting the
virtual space between blood vessels and pia mater, by them-
selves are a physiologic finding. It is the enlargement of
these spaces that can be seen on MRI, which is considered
nonphysiologic. The question then remains what amount
of enlargement should distinguish physiologic from nonphy-
siologic perivascular spaces? Originally, a convenience
threshold was chosen such that any perivascular space
visible on brain MRI was considered enlarged. However,
increasing field strengths and other advances in imaging
now allow much smaller perivascular spaces to become
visible on MRI, indicating the need to use a more objective
and reproducible threshold independent from imaging pa-
rameters.
Second, because perivascular spaces are defined by their
intricate relation to brain vessels, they are ubiquitous in all
brain regions. Yet, the extent of enlargement is different
across brain regions and should be taken into account in their
quantification. A working upper width limit of 3 mm is
widely used to discriminate perivascular spaces from small
lacunes [5], but, for example, it is well recognized that peri-
vascular spaces of larger width are sometimes seen in the
substantia innominata. Radiopathological correlation
studies show that MRI can differentiate perivascular spaces
from lacunes with good sensitivity and specificity using
morphological and signal-intensity information [24], but
more validation on correlations by region would be
welcome. Similarly, the processes underlying their enlarge-
ment are thought to differ according to brain region; for
example, in cerebral amyloid angiopathy, enlargement of
perivascular spaces is seen in the centrum semiovale but
not in the basal ganglia [25,26].
Against this background, it is not surprising that the
various efforts to quantify perivascular spaces have differed
with respect to definition of enlargement, regions to be
scored, and scoring system used [23,27–30]. Although
work continues to identify the key features of these rating
systems with respect to similarities, dissimilarities,
strengths, weaknesses, and “translation” from one rating
system to the other, we recommend that investigators use
the rating system most relevant to their population, or that
they are most comfortable with, while having a core
understanding how that specific rating system relates to
others available in the literature. Raters should be trained
on a standardized data set with measurement of intrarater
and interrater reliability and report these measures in
publications; training tools are available on HARNESS
website.
Parallel to this development of visual rating, there is now
a strong focus on fully-automated quantification of perivas-
cular spaces. These efforts have so far been hampered by
similar methodological considerations as outlined previ-
ously in this article, but the recent introduction of machine
learning algorithms in brain imaging holds great promise
in overcoming these barriers [22,31]. Just like how
automated quantification of WMH resulted in dramatic
improvement in our understanding of their role in
neurodegenerative diseases particularly at the voxel level,
automated detection, volumetrics, shape, density, and
orientation of perivascular spaces could signify a paradigm
shift in their position within the pantheon of cSVD markers.
3.4. Structural imaging: atrophy in the context of cSVD
Atrophy is now a well-established, measurable conse-
quence of cSVD. Both cross-sectional and longitudinal
studies show proof of principle that total brain volume is
lower in cSVD and decreases more quickly in persons
with enlarging WMH. The repeatability and reproducibility
of brain volume measurements in the context of cSVD has
been reviewed recently [17]. Here, we highlight specific as-
pects to be considered when implementing atrophymeasure-
ments in cSVD studies.
Given the complexity of brain anatomy, measures of
brain volume should be obtained from 3D T1-weighted
high-resolution isotropic sequences with quantitative
computerized methods where possible. To capture chronic
final effects, the image acquisitions should be performed
remotely in time (probably 90 days or longer) from the
occurrence of acute brain lesions.
At a given time point, volumetric measures reflect the
sum of the individual’s maximum brain volume growth (esti-
mated by the intracranial cavity volume), the effect of age,
and the effect of multiple potential diseases including
cSVD, overt stroke, and neurodegenerative diseases such
as Alzheimer’s disease. Controlling for differences in head
size, for example, by expressing volumes as a fraction of
intracranial volume or including intracranial volume as a co-
variate, is mandatory in single time point analyses. Although
controlling for intracranial volume is not strictly necessary
for longitudinal analyses, investigators may still want to
analyze it as a proxy for original maximum brain size, which
reflects premorbid brain health and is associated with gen-
eral intelligence [32]. In longitudinal analyses, the use of
cross-timepoint registration pipelines rather than the
repeated use of cross-sectional methods may reduce vari-
ability in measurement [33,34], but the optimal approach
remains to be confirmed.
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Methods involving registration to a common template
should be used cautiously given that brains with cSVD, often
exhibiting large ventricles and white matter atrophy, can reg-
ister poorly to atlases based on healthy individuals. This is a
particularly challenging problem when cSVD is accompa-
nied by larger destructive intracerebral hemorrhages or in-
farcts. The impact of brain tissue lesions on the different
methods to assess brain volume is often unpredictable
[35]. In particular, the presence of extensive WMH can
lead to erratic behavior of most algorithms [36,37], and if
appropriate, they should be masked. In addition,
algorithms may variably segment fluid-filled cavities within
the brain (lacunes and enlarged perivascular spaces) as cere-
brospinal fluid, gray matter, or white matter, requiring a sys-
tematic visual quality control of segmentation results
[35,38]. There is consensus that cavities resulting from
infarction should be excluded from brain tissue estimates
[5], depending on the question being asked; clearly, they
do not represent spaces such as subarachnoid space or ven-
tricles, nor do they represent normal brain tissue. They can
be considered as part of the “total burden of brain injury”
[39] in some analyses. Quantitative methods that can esti-
mate perivascular space volume are emerging; when such
measurements are made, we recommend that perivascular
space volume be reported as a separate tissue class and not
included in the total brain volume. Given the numerous sour-
ces of variation in gray to white contrast in cSVD, differen-
tial measures of gray and white matter volumes should be
interpreted carefully [40]. The use of other computational
volumetric markers, such as ventricle volumes, has not
been validated in cSVD. All methods require visual check-
ing and may need manual editing where automated segmen-
tation has failed to identify the correct tissue.
3.5. Diffusion imaging metrics
Diffusion imaging provides data on the diffusion of water
molecules within brain tissue. There are a large variety of
techniques to analyze these data.Diffusion-weighted imaging
is positive (i.e., shows increased signal) in the setting of recent
infarction or microinfarction. Scalar measures describe diffu-
sion properties on the voxel level, such as the extent or direc-
tionality. Diffusion tensor imaging (DTI) is the most useful
model to derive these scalar metrics such as mean diffusivity
(MD) or fractional anisotropy (FA). Tractography can be used
to visualize fiber connections and analyze diffusion on the
tract level. Global tractography in combination with graph
theoretical network analysis allows assessment of the impact
of cSVD on the level of brain networks.
Proof of principle that diffusion imagingmetrics can serve
as biomarkers of cSVD iswell established bymultiple studies
associating diffusion imaging indices derived from the white
matter or normal-appearing white matter (NAWM) with
cSVD and cSVD risk factors. Most studies report cross-
sectional associations between lower FA or higher MD and
cognitive and gait impairments [41,42]. MD is readily
measured in the whole brain, tissue subregions, regions of
interest, or tracts and shows the strongest associations with
SVD lesion burden [43]. Recent, promising postprocessing
methods to increase the reliability and ease of extraction of
diffusion imaging metrics include histogram-derived diffu-
sion imaging metrics, such as the peak width of the skeleton-
ized MD distribution [44], and connectivity measures
including those based on network theory [45–47]. Lower
brain connectivity in strategic network locations, such as
long-distance fibers connecting so-called network “hubs”,
shows promise for prediction of speed and executive func-
tioning [48,49]. This is not an exhaustive list as there are
several other promising diffusion imaging acquisition and
analysis methods that show promise for development as
biomarkers of cSVD [50,51].
In contrast to the many cross-sectional studies, there are
fewer studies evaluating diffusion imaging as a prognostic
marker of disease progression [41]. The leukoaraiosis and
disability study reported an association between NAWM MD
at baseline and decline in the processing speed [52], whereas
the Radboud University Nijmegen Diffusion Tensor and Mag-
netic Resonance Cohort study found no association between
baseline NAWMMD and cognitive decline [53] or risk of de-
mentia over 5 years [54]. Diffusion imaging–derived brain con-
nectivity predicted conversion to dementia after 5 years [55].
Longitudinal studies of diffusion imaging changes over time
are, at this time, relatively scarce [56–60] but promising,
suggesting that changes over time can be detected on
diffusion imaging with similar sensitivity as changes over
time in WMH volume, requiring smaller sample sizes than
required to detect atrophy or incident lacunes [61]. Progression
over time in diffusion imagingmetrics has been associatedwith
increased risk of dementia [58] and gait decline [62].
The tissue correlate of altered diffusion metrics in cSVD
is still debated. A recent study suggests that increased extra-
cellular water content is a major contributor [50].
There are few studies on repeatability and reproducibility.
Only one study with patients with cSVD showed high repro-
ducibility of peak width of the skeletonized MD distribution
in 7 patients with CADASIL scanned by using a 1.5Tand 3T
scanner (intraclass correlation 0.95) [44]. Other studies in
healthy controls have shown good repeatability and repro-
ducibility for FA and MDmeasurements (coefficient of vari-
ation ranging from 0.8% to 5.7%) [63–65]. Nonetheless,
variation in scanner or scanner upgrades may bias
measurements in longitudinal studies [63]; therefore, inves-
tigators ideally should avoid scanner upgrades or changing
scanners between baseline and follow-up measurements in
studies designed to detect small changes over time. Phan-
toms to estimate reproducibility are in development [66].
3.6. Perfusion and cerebrovascular reactivity
Perfusion and cerebrovascular reactivity (CVR) ap-
proaches are highly relevant in cSVD research because
reduced tissue perfusion and impaired CVR are hallmark
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pathological features. These physiological forms of imaging
introduce a unique set of challenges for study design, given
the large variability in acquisition methods for perfusion
especially CVR which are less well established than many
structural imaging techniques. To image CVR, the investi-
gator must choose among several experimental methods
for stimulating changes in cerebral blood flow (CBF) and
among several different acquisition types, such as blood ox-
ygen level dependent (BOLD) or ASL. Because the vascular
signal comes from only a proportion of voxel contents (the
blood volume fraction in gray matter accounts for 5 to
10% of the tissue volume) and the changes in hemoglobin
oxygenation are relatively small for BOLD-related tech-
niques, attention must be paid to ensure sufficient signal-
to-noise ratio to generate images of adequate quality.
Dynamic susceptibility contrast and ASL are examples of
MRI acquisitions that yield perfusion-weighted images; the
former relies on an exogenous gadolinium contrast agent,
whereas the latter uses magnetically labeled arterial blood
water that is proximal to the imaging volume to label blood
and produces quantitative perfusion maps typically ex-
pressed in units of mL/100g tissue/minute.
ASL is a promisingmodality for repeated-measure studies
because it does not require administration of an exogenous
intravenous contrast agent. A fraction of cSVD articles on
perfusion have thus far used ASL [67]; cross-sectional
studies, for example, provide proof of principle by showing
that a pattern of reduced frontal perfusion was associated
with increased WMH volume [68]. Longitudinal studies are
less common, however, one 4-year follow-up study reported
that global CBF decreases were associated with higher base-
lineWMHbut also that baselineCBFwas not associatedwith
greater WMH progression [69]. Another longitudinal study
found that although lower baseline CBF predicted appear-
ance of new WMH at 18 months, changes in CBF were not
associatedwith newWMH[70]. Studies are needed on the as-
sociation of baseline and longitudinal CBF and the preva-
lence and incidence of new brain infarcts and microinfarcts.
Although white matter and subcortical tissue perfusion esti-
mates are of particular interest in cSVD, these measurements
are less robust than those in graymatter when usingASL [71]
due to the lower CBF and longer arterial transit time.
A validation study of ASL found higher repeatability for
pseudo-continuous ASL than for pulsed ASL or continuous
ASL, with a coefficient of variation of 3.5% in gray matter
and 8.0% in white matter [72]. There are few reproducibility
studies across scanner types. One study found high repro-
ducibility in eight volunteers scanned by using two General
Electric (GE) 3T scanners [73]. Another study found that
sequence parameter differences had a larger effect than hard-
ware or software differences on General Electric, Philips,
and Siemens scanners [74]. Phantoms for ASL have been
developed but not yet widely adopted [75].
Unlike physiological imaging during a single “baseline”
state, CVR involves physiological provocation to measure
a vasoactive response, typically by breathing medical air
enriched with carbon dioxide gas. Technical and paradigm
details and considerations have been recently reviewed
[76]. Multicontrast physiological imaging, combining perfu-
sion and CVR maps in cSVD, is a promising technique [77].
At this time, relatively fewCVR studies have focused explic-
itly on cSVD [78]. However, CVR imaging is being exploited
as an imaging endpoint to assess the efficacy of vasodilatory
drugs in a dose-escalation trial [79]. CVR appears to be a
promising prognostic biomarker of cSVD brain changes,
for example, as revealed by one longitudinal study that found
impaired regional CVR was predictive of WMH lesion
expansion at one-year follow-up [80]. A four-year longitudi-
nal study showed that age-related decreases in CVR were
associated with steeper declines in processing speed and
episodic memory but not working memory or reasoning;
however, the degree to which enlargingWMH or new infarc-
tionmay have been associated with these changes was not as-
sessed. The BOLD response to a visual stimulus has been
shown to be a possible biomarker for cerebral amyloid angi-
opathy and could be a more easily implemented, well-
tolerated alternative means to measure CVR, but is limited
to the occipital lobe [81–83] and has not been compared
directly to CVR measurement based on hypercapnia.
The repeatability of CVR measurements has been inves-
tigated in healthy controls but not in patients with cSVD. In a
study of 15 controls, the coefficient of variation ranged from
7.3% to 42.9% across 16 regions of interest, including
cortical and subcortical gray matter and white matter [84].
The coefficient of variation was lower when using a para-
digm that averaged two three-minute blocks of CO2 inhala-
tion rather than three one-minute blocks [84].
A consensus group has provided recommendations for
ASL imaging protocols [85]; however, long-label and
long-delay ASL approaches may prove superior for CBF
measurement in the white matter and subcortical gray mat-
ter. Multicenter studies using scanners from different ven-
dors seem justifiable as long as key methods (including
choice of pseudocontinuous ASL, readout strategy, labeling
duration, and postlabeling delay time) are kept constant. For
CVR imaging, there is a greater diversity of methods, and the
different methods may suit specific patient populations. One
published protocol [84] using three-minute CO2 blocks is
being used in a multicenter trial.
3.7. Blood-brain barrier integrity
Although proof-of-concept evidence is very limited,
proof-of-principle evidence from cross-sectional clinical
studies suggests that blood-brain barrier (BBB) dysfunction
determined by magnetic resonance (MR) is associated with
imaging features of cSVD and that BBB leakage may
contribute to tissue damage, development of cSVD features,
and long-term adverse outcomes [86,87]. Therefore, BBB
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permeability is an important target of measurement in
studies of pathophysiology and treatment evaluation.
Dynamic contrast-enhanced MRI (DCE-MRI) using a
standard dose of a gadolinium-based contrast agent
(GBCA) is presently the most promising technique for quan-
titative imaging of subtle leakage [86] and has been applied
in several studies of cSVD and related conditions [86,88–
91]. However, while the technique is well-established in
other conditions such as brain tumors, particular challenges
emerge in cSVD due to the slow rate of leakage. For quali-
tative assessment, GBCA enhancement of cerebrospinal
fluid on T2-weighted fluid-attenuated inversion recovery
and T1-weighted imaging may provide a practical, but
nonspecific, alternative [92,93]. Other potential methods
are difficult to quantify (e.g., dynamic susceptibility
contrast MRI) [94], use ionising radiation [95,96], or are at
an early stage of development (compartmental ASL
modeling [97–99]). Nevertheless, DCE-MRI is not routinely
used in cSVD studies due to practical impediments (long
scan time, exogenous contrast), lack of widespread exper-
tise, and technical and physiological complexities and con-
founds [100,101].
There are few studies of BBB permeability change over
time in cSVD. A single study of 22 subjects with high
WMH burden reported little overlap between regions of
high white matter permeability between the first and second
scans, but that high permeability was often seen along the
border of WMH at either time [102].
Because there is no reliable convenient reference method
for quantifying subtle BBB permeability, studies comparing
DCE-MRI measurements with other measures of BBB integ-
rity are few and inconclusive [103,104]. The need for a
second gadolinium administration is a barrier to conducting
studies on repeatability, but one study showed good evidence
of repeatability with coefficient of variation of 11.6% for
whitematter and 14.4% for graymatter at 3T [105]. Reproduc-
ibility across differentMRhardware has not been investigated.
Based on theoretical considerations and experimental observa-
tions, it is likely thatmeasurements are influenced byMRfield
strength, scanner stability, spatial resolution, pulse sequence
parameters, acquisition time, GBCA type, and pharmacoki-
netic model [100,101,106,107]. The diversity of acquisition
and analysis protocols described (sometimes incompletely)
in the literature is, therefore, a key impediment to the
interpretation and comparison of data from different studies
and centers.
Our recommendation for future studies is to use a three-
dimensional, MR acquisition with wide spatial coverage,
precontrast T1 measurement, a minimum temporal resolu-
tion of around one minute, and a minimum DCE scan time
of 15 minutes [108]. A vascular input function should be
measured in the venous sinuses, and the permeability-
surface area product for tissue regions or, where feasible, in-
dividual voxels should be estimated using an appropriate
pharmacokinetic model, typically the Patlak model [109];
simulations may be performed to assess accuracy and preci-
sion. Results should be interpreted carefully, particularly
when comparing data from different research groups or
scanners. We identified three priorities for the development
of this biomarker: (1) agreement by the wider cSVD and de-
mentia imaging research community on an open-access, dy-
namic consensus protocol for DCE-MRI measurements of
slow BBB leakage; (2) acquisition of data on repeatability
and reproducibility; and (3) studies to assess accuracy,
including theoretical work, comparison with independent
measures of BBB integrity, and validation using MR test ob-
jects and histology. Further technical development to in-
crease accuracy and precision, as well as continued
development of alternative methods, is also encouraged.
3.8. Ultra-high-field MRI
Ultra-high-fieldMRI, in particular 7TMRI, is emerging as
a new tool in cSVD research. The higher resolution, different
tissue contrasts, and better signal-to-noise ratios of 7T MRI
allow the investigator to probe aspects of cSVD that are diffi-
cult to assess at lower field strength. In addition to enhanced
sensitivity for cSVD lesions such as microinfarcts and micro-
bleeds and more precise assessment of atrophy [18,110], with
7T MRI, it is possible to actually visualize the small vessels
[111]. From both perforating arteries and veins, features such
as vessel density, length, and tortuosity can be resolved
[111,112]. In addition, different aspects of vascular
function, including blood flow, pulsatility of flow in small
penetrating arteries (a possible indicator of vascular
stiffness), vascular reactivity to vasoactive agents (e.g.,
carbon dioxide), or neuronal stimulation (i.e., functional
MRI), can be assessed, making it possible to probe cSVD
at the level of the small vessels themselves [111].
Despite the potential of 7T MRI in cSVD research,
important steps have to be taken to validate these novel tech-
niques. Of note, the European Ultrahigh-Field Imaging
Network in Neurodegenerative Diseases (EUFIND), another
Joint Program on Neurodegenerative Diseases initiative, has
the goal of harmonizing 7T MRI protocols across more than
20 centers from Europe and the United States.
3.9. Tools to facilitate cSVD biomarker development and
harmonization
The HARNESS initiative focused on three areas to pro-
vide tools for harmonization: MR acquisition, postprocess-
ing, and common repositories for training and validation.
These tools are made available to the research community
at www.harness-neuroimaging.org.
The HARNESS website provides fully specified MR
acquisition protocols suitable for research studies that have
a focus on cSVD. Given the diversity of manifestations of
cSVD and hypotheses that can be tested, there is no single
MR acquisition protocol that can quantify all aspects of
cSVD, and therefore, investigators must make choices
regarding protocol composition, also accounting for issues
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of feasibility including acquisition time and cost. Therefore,
instead of a single protocol, the HARNESS website provides
several options that meet these criteria: (1) they adhere to
STRIVE [5]; (2) they are suitable for identifying types of ca-
nonical cSVD lesions—lacunes and WMH of presumed
vascular origin, recent small infarcts, microbleeds, atrophy,
and DTI changes; (3) they have been tested on more than
one scanner as part of an established multicenter study;
and (4) the protocol developers are willing to share the pro-
tocol freely. There are also links to other websites and useful
repositories of information.
Currently, protocols are available from the SVD@target
study [84] (ISRCTN10514229) and the Canadian Dementia
Imaging Protocol [113], with plans to add the protocol
from the US National Institute of Neurological Disorders
and Stroke MarkVCID Biomarker Consortium (https://
markvcid.partners.org/) once it has been fully specified and
tested. Sequence parameters with examination cards are pro-
vided for 3T formost of themajor vendors, includingGeneral
Electric, Phillips, and Siemens. The protocols are suitable for
prospective research studies with quantitative imaging bio-
markers but probably exceed most clinical stroke protocols
in terms of acquisition time, spatial resolution, and inclusion
of DTI. They have been implemented successfully in multi-
center studies at research sites, but nonetheless may not be
feasible for multicenter studies performed at predominantly
clinical scan sites where the intent is to leverage clinical im-
aging without a focus on quantitative biomarkers.
Reducing imaging variability may be enhanced by
following consensus recommendations [17] to perform auto-
mated quality checks for acquisition parameters and moni-
toring of images for artifacts, correction for gradient
nonlinearities, a well-defined method for subject’s posi-
tioning in the scanner, and a clear strategy for hardware
replacement when needed.
The HARNESS software database serves as a searchable
source for information on downloadable software tools for
processing MR data for cSVD quantitative biomarkers,
such as for segmenting WMH. There are many existing soft-
ware libraries for neuroimaging analysis, but only
HARNESS focuses exclusively on cSVD. Site users can
search for software by image modality, measurement type,
key words, availability (i.e., by download or by request to
the developer), or operating system. Software developers
control their own entries via password-protected accounts
and must make their software available according to their
own terms by providing a link or through contacting the
developer. We are actively recruiting developers with tools
to sell or share. Developers may access the site for informa-
tion on how to create accounts.
To aid visual review for cSVD lesions according to
STRIVE, theHARNESS sitemakes downloadable electronic
documents available, including validated visual rating scale
scores and instructions, case report forms, and training slides.
Training readers and software algorithms require access
to independent MR data sets for measurements. The
HARNESS site includes a Web-based repository with
completely deidentified 3T MR data showing lacunes,
WMH, microbleeds, and cortical superficial siderosis from
patients with TIA, minor ischemic stroke, and cerebral am-
yloid angiopathy, with consensus “gold standard” measure-
ments for comparison. This repository will be useful for
independently confirming reliability of measurements
within and across research groups and for derivation and
validation of computerized algorithms for quantitative mea-
surement (e.g., for segmenting WMH to determine location
and overall volume), as well as for comparing WMH algo-
rithms against an independent standard.
4. Summary and conclusions
The HARNESS initiative was a multidisciplinary
consensus process with input from a large number of neuro-
imaging researchers investigating cSVD. Our group
developed a framework for neuroimaging biomarker devel-
opment closely aligned with those proposed in other areas
of imaging research. The HARNESS website (www.
harness-neuroimaging.org) was created to facilitate harmo-
nized neuroimaging methods for cSVD research. The site in-
cludes cSVD-appropriate MR acquisition protocols aligned
with STRIVE [5], a searchable database of software pro-
grams for analyzing brains with cSVD, visual rating scales
and case report forms, and a repository of 100 deidentified
scans demonstrating different cSVD lesion types. These
tools and resources are made available to the research com-
munity via the site and can be easily updated by contributors.
In this rapidly evolving field, we found that the degree of
biomarker validation—technical, biological, and clinical
and feasibility—varied by cSVD lesion and measurement
type. In general, visually diagnosed cSVD lesions such as la-
cunes, WMH, and microbleeds have the greatest amount of
clinical validation, as prognostic markers, and data are avail-
able on incidence and change over time and are already be-
ing used in multicenter studies and reported in routine
clinical practice. Even so, none of these markers has yet
been qualified for use in clinical trials by regulatory
agencies, and more work is needed to standardize and
compare current volumetric tools. Other markers are at a
less advanced stage of biomarker development. Atrophy
has been extensively studied but almost always in the
context of Alzheimer’s disease and not cSVD. Among the
emerging cSVD markers, there are relatively more data on
diffusion imaging and perivascular space imaging, but
more longitudinal data and multicenter data on reproduc-
ibility are needed. Measurements of brain perfusion,
vascular reactivity, and BBB integrity are promising but
are at an even earlier stage of development. For these
cSVD manifestations, innovation to overcome technical
and feasibility barriers, rather than harmonizing to a best
protocol, is the most important next step in development.
We found that technical validation often lagged clinical
validation. However, estimates of repeatability and
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reproducibility are critically important to estimate minimum
detectable differences over time and variability in measure-
ment in multicenter studies, which are essential for sample
size calculations for multicenter longitudinal trials. This
lag in technical validation likely reflects the difficulty in ob-
taining funding for technical studies compared with clinical
studies, the burden on research subjects to undergo multiple
scans, and the general lack of nonhuman phantoms for
studies of reproducibility. In contrast to volumetric imaging
and functional MRI, phantoms for other measurements are
less well developed. One research group has developed a
phantom for iron deposits that mimic mineral deposits and
microbleeds, not currently available for purchase [114];
otherwise, we are not aware of any other phantoms that
recreate specific aspects of cSVD. Technical validation for
neuroimaging biomarkers of cSVD would be enhanced by
creating funding opportunities specifically for this purpose.
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RESEARCH IN CONTEXT
1. Systematic review: Working groups identified rele-
vant papers through literature searches, expert
knowledge, and hand searching articles from refer-
ence lists, but formal systematic reviews and creation
of evidence tables were not within scope.
2. Interpretation: To help harmonize methods for neu-
roimaging research on cerebral small vessel disease
we developed a framework for neuroimaging
biomarker development, reviewed the status of
development of established and emerging neuroi-
maging biomarkers of cerebral small vessel disease
within this framework, and created a website
(www.harness-neuroimaging.org) with MR acquisi-
tion protocols, a searchable database of software
for quantitative brain imaging analysis of cerebral
small vessel disease, visual rating scales and case
report forms, and a repository of deidentified scans
demonstrating different lesion types.
3. Future directions: The HARNESS initiative provides
resources to reduce variability in measurement in
MRI studies of cerebral small vessel disease that
should facilitate multicenter studies and clinical trials.
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